SCHEMBL2473690

SCHEMBL2473690

Cc1onc(-c2ccccc2)c1-c1cn(-c2ccccn2)cn1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGS2 P35354 6/20 0.51
PTGS1 P23219 4/20 0.51
MAPT P10636 5/20 0.45
MAPK14 Q16539 2/20 0.45
GABRA5 P31644 2/20 0.43
TDP1 Q9NUW8 1/20 0.42
L3MBTL1 Q9Y468 1/20 0.42
MT-CO2 P00403 3/20 0.41
CA12 O43570 1/20 0.41
CA1 P00915 1/20 0.41
CA2 P00918 1/20 0.41
LMNA P02545 1/20 0.41
CA3 P07451 1/20 0.41
ADRB2 P07550 1/20 0.41
ADRB1 P08588 1/20 0.41
CYP3A4 P08684 1/20 0.41
ADORA3 P0DMS8 1/20 0.41
CHRM1 P11229 1/20 0.41
ADRA2B P18089 1/20 0.41
CA4 P22748 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2472128 0.88 PTGS2 (0.54) PTGS2PTGS1MAPTMAPK14GABRA5
SCHEMBL2470757 0.85 PTGS2 (0.56) PTGS2PTGS1MAPTMAPK14TDP1
SCHEMBL2477859 0.81 HTT (0.55) PTGS2PTGS1MAPTMAPK14TDP1
SCHEMBL2472121 0.80 PTGS2 (0.50) PTGS2PTGS1MAPTMAPK14TDP1
SCHEMBL2471444 0.80 PTGS1 (0.50) PTGS2PTGS1MAPTMAPK14TDP1
SCHEMBL2473755 0.80 PTGS2 (0.50) PTGS2PTGS1MAPTMAPK14TDP1
SCHEMBL2468959 0.80 PTGS2 (0.50) PTGS2PTGS1MAPTMAPK14TDP1
SCHEMBL2470820 0.80 PTGS2 (0.50) PTGS2PTGS1MAPTMAPK14TDP1
SCHEMBL2471844 0.80 NPC1 (0.61) PTGS2PTGS1MAPTMAPK14GABRA5
SCHEMBL2470539 0.78 PTGS2 (0.48) PTGS2PTGS1MAPTMAPK14GABRA5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1968973-B1 ARYL-ISOXAZOL-4-YL-IMIDAZOLE DERIVATIVES HOFFMANN LA ROCHE (CH) 2011-10-05 EP claimed
US-7414061-B2 Aryl-isoxazol-4-yl-imidazole derivatives HOFFMANN-LA ROCHE INC. (US) 2008-08-19 US claimed
US-20070161654-A1 Aryl-isoxazol-4-yl-imidazole derivatives HOFFMANN-LA ROCHE INC. 2007-07-12 US claimed
EP-1968973-B1 ARYL-ISOXAZOL-4-YL-IMIDAZOLE DERIVATIVES HOFFMANN LA ROCHE (CH) 2011-10-05 EP disclosed
US-7414061-B2 Aryl-isoxazol-4-yl-imidazole derivatives HOFFMANN-LA ROCHE INC. (US) 2008-08-19 US disclosed
US-20070161654-A1 Aryl-isoxazol-4-yl-imidazole derivatives HOFFMANN-LA ROCHE INC. 2007-07-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070161654-A1 Aryl-isoxazol-4-yl-imidazole derivatives GABRA5, GABRA4, GABRA1 PTGS2 3762/4885PTGS1 2693/4885MAPT 254/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.